Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03073343
Other study ID # Betaine 2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 12, 2013
Est. completion date December 30, 2025

Study information

Verified date May 2024
Source Southern California Institute for Research and Education
Contact Timothy R Morgan, MD
Phone 562-826-5212
Email timothy.morgan@va.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.


Description:

This is a prospective, unblinded, randomized study of oral betaine in diabetic and non-diabetic patients who have a clinical diagnosis of NAFLD and an ALT≥ 50 IU/mL. A clinical diagnosis of NAFLD is based on the presence of risk factors for NAFLD (such as overweight and insulin resistance) and the exclusion of other causes of liver disease, such as alcohol or viral hepatitis. Two cohorts of patients will be studied: Cohort 1 (diabetic) will consist of patients with a clinical diagnosis of non-insulin dependent type II diabetes mellitus; Cohort 2 (non-diabetics) will consist of patients without a clinical diagnosis of type 2 diabetes mellitus. 24 patients will be enrolled in each cohort (total of 48 patients enrolled in the study) with an anticipated drop out of 4 subjects per cohort. Patients will be given dietary instructions and advice on exercise appropriate for the management of NAFLD (NIDDK and liverfoundation.org handouts). Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort (NIDDM and non-diabetic) will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks. All patients will be seen in clinic on a monthly basis during treatment, and again 4 and 12 weeks after completion of betaine treatment. The total duration of the study is 24 weeks (12 weeks of betaine treatment and 12 weeks of follow-up). The primary outcome is change in ALT during 12 weeks of betaine treatment (i.e., ALT at week 12 compared with ALT at baseline (entry). Secondary outcomes include safety, efficacy of betaine in each cohort, and are changes in laboratory tests related to NAFLD.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date December 30, 2025
Est. primary completion date December 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: Inclusion Criteria for all patients: 1. Age 18-75 years 2. A clinical diagnosis of non-alcoholic fatty liver disease. 3. Alanine aminotransferase (ALT) levels =60 IU/mL 4. Laboratory tests as defined below: - Platelets > 100,000/dL - Total bilirubin < 2 mg/dL - Creatinine < 1.6 mg/dL - Inclusion Criteria for Group 1: diabetic patients 1. At least one of the following: - Fasting blood sugar = 126mg/dL - Hemoglobin A1c (HgA1c) of > 6.5% - 2-hour plasma glucose level of > 200mg/dL during a glucose tolerance test - Receiving treatment with insulin sensitizing drugs (metformin) or sulfonylureas (glipizide, etc.) 3. Inclusion Criteria for Group 2: Non-diabetic patients with insulin resistance (must have both) - Fasting blood glucose of 100-125 mg/dL and - Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score >3.0 Exclusion Criteria: 1. Evidence of liver disease other than non-alcoholic fatty liver disease or non-alcoholic steatohepatitis 2. Alcohol consumption of more than 12g/d (1 drink) for females or more than 24g/day (2 drinks) for males, for 3 months during the past year 3. Active substance abuse within the past year 4. Prior or ongoing use of injectable insulin 5. Use of oral corticosteroids within the prior 30 days 6. Hospitalization within the past 14 days 7. Known HIV infection 8. HgA1c >10% 9. Known heart failure of New York Heart Association class 2, 3, or 4 10. Any condition, which in the opinion of the investigator, would impede compliance or hinder the completion of the study 11. History of allergic reactions attributed to compounds of similar chemical or biologic composition to betaine 12. Current use of betaine or S-adenosylmethionine supplements, or refusal to abstain from their use during the study 13. Known cystathionine beta-synthase (CBS) deficiency. 14. Pregnancy or refusal to use birth control measures or breast feeding

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Betaine (trimethyglycine)
Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.

Locations

Country Name City State
United States VA Long Beach Healthcare System Long Beach California

Sponsors (1)

Lead Sponsor Collaborator
Southern California Institute for Research and Education

Country where clinical trial is conducted

United States, 

References & Publications (2)

Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999 Mar;29(3):664-9. doi: 10.1002/hep.510290347. — View Citation

Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999 Jun;116(6):1413-9. doi: 10.1016/s0016-5085(99)70506-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in alanine aminotransferase (ALT) level in all study participants Compare the week 12 ALT levels with the baseline ALT in study patients. Comparison will be performed using a paired t-test. after 12 weeks of Betaine
Secondary Compare changes in alanine aminotransferase (ALT) level in both cohorts A Paired T test analysis will compare changes in ALT levels between Patients with NIDDM (cohort 1) and Patients without NIDDM (cohort 2) after 12 weeks of Betaine
See also
  Status Clinical Trial Phase
Recruiting NCT05480696 - Soluble Fibre Supplementation in NAFLD Phase 1
Active, not recruiting NCT02500147 - Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT04671186 - Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan N/A
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT05462353 - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH Phase 2
Completed NCT05006885 - ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) Phase 1
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Recruiting NCT05618626 - Prevention of NAFLD and CVD Through Lifestyle Intervention N/A
Completed NCT03256526 - 6-week Safety and PD Study in Adults With NAFLD Phase 2
Enrolling by invitation NCT06152991 - Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy Phase 3
Completed NCT03681457 - Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects Phase 1
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Completed NCT03060694 - Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
Completed NCT02526732 - Hepatic Inflammation and Physical Performance in Patients With NASH N/A
Recruiting NCT01988441 - The Influence of Autophagy on Fatty Liver
Recruiting NCT01680003 - Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease Phase 2
Completed NCT01712711 - Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease Phase 2
Recruiting NCT00941642 - Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Phase 4